CURRICULUM VITAE

Edmond T. Conway, FNP-C

Quality Medical Research
330 Wallace Road, Suite 103
Nashville, TN 37211

Nashville Gastroenterology and Hepatology, PC
330 Wallace Road, Suite 103
Nashville, TN 37211

Southern Endoscopy Center
330 Wallace Road, Suite 103
Nashville, TN 37211

Office: 615-832-5530
Fax: 615-835-4755

CERTIFICATION AND LICENSURE

American Academy of Nurse Practitioners, #F0897120
Certification of Fitness to Prescribe, #1330
Tennessee Board of Nursing, RN#110453; original license issued 12-02-1996
Tennessee Board of Nursing, Advanced Practice Nurse, APN#7406; original license issued 08-13-2004
American Heart Association, BLS

PROFESSIONAL MEMBERSHIPS

American Gastroenterological Association (AGA)
American Association for the Study of Liver Diseases (AASLD)
European Association for the Study of the Liver (EASL)

CURRICULUM VITAE

Edmond T. Conway, FNP-C

NON MEDICAL EXTRACURRICULAR ACTIVITIES

St Mark's Episcopal Church, Member of the Vestry , since 2014

EDUCATION

1996	Master's of Science in Nursing (Bridging Program with Bachelor's of Science in Nursing) University of Tennessee-Knoxville Knoxville, Tennessee
1996	Bachelor's of Science in Nursing (Bridging Program with Master's of Science in Nursing) University of Tennessee-Knoxville Knoxville, Tennessee
1996	Sigma Theta Tau, Practitioner Advanced Level Scholastic Society
1993	Emergency Medical Technician Roane State Community College Knoxville, Tennessee
1990	Bachelor's of Arts, Philosophy, Cum Laude Emory University Atlanta, Georgia

CURRICULUM VITAE

Edmond T. Conway, FNP-C

PROFESSIONAL EXPERIENCE

2001-present **Nurse Practitioner**
Nashville Gastroenterology and Hepatology, PC
Quality Medical Research
Nashville, Tennessee

* Supervised provider of medical services focusing on acute and chronic disease of gastroenterology and hepatology.
* Secondary focus on research.

1999-2001 **Nurse Practitioner**
First Care Medical Clinic
Knoxville, Tennessee

* Autonomous and supervised provider of medical services in an urban setting with a primary focus on occupational medicine.
* Managed 24-hour on-call service, phone triage.

1997-1999 **Nurse Practitioner**
Rutledge Clinic
Lewisburg, Tennessee

* Autonomous provider of medical services in a rural setting, with primary adult and geriatric populations.

1996-1997 **Nurse Practitioner**
Lewisburg Medical Clinic
Lewisburg, Tennessee

* Autonomous provider of medical services in a rural setting, broad spectrum practice ranging from pediatrics to geriatrics, treating acute and chronic disease process.

CURRICULUM VITAE

Edmond T. Conway, FNP-C

CONTINUING MEDICAL EDUCATION COURSES (CME)

2018 OnCourse Learning 30Apr2018
Advanced Practice Nurse Pharmacology (60185)
25 contact hours

2017 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Orlando, FL.
16.75 AMA PRA Category 1 Credits™

2017 American College of Gastroenterology (ACG)
Annual Physician Postgraduate Course, Orlando, FL.
13 AMA PRA Category 1 Credits™

2015 Vanderbilt University School of Medicine
2015 Gastroenterology, Hepatology and Nutrition Update
Nashville, TN
11 AMA PRA Category 1 Credits

2014 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Philadelphia, PA.
16.25 AMA PRA Category 1 Credits™

2014 American College of Gastroenterology (ACG)
Annual Physician Postgraduate Course, Philadelphia, PA.
13.25 AMA PRA Category 1 Credits™

2014 American College of Gastroenterology (ACG)
Annual Postgraduate Course, Philadelphia, PA.
Learning Luncheons 20,
1.00 AMA PRA Category 1 Credits™

2014 American College of Gastroenterology (ACG)
Annual Postgraduate Course, Philadelphia, PA.
Learning Luncheons 9,
1.00 AMA PRA Category 1 Credits™

2013 American College of Gastroenterology (ACG)
Annual Scientific Meeting, San Diego, CA.
16.25 AMA PRA Category 1 Credits™

2013 American College of Gastroenterology (ACG)
Annual Physician Postgraduate Course, San Diego, CA.
13.25 AMA PRA Category 1 Credits™

2012 American College of Gastroenterology (ACG)
Annual Scientific Meeting Las Vegas, Nevada.
16.25 AMA PRA Category 1 Credits™

2012 American College of Gastroenterology (ACG)
Annual Physician Postgraduate Course, Las Vegas, NV.
13.25 AMA PRA Category 1 Credits™

2011 American College of Gastroenterology (ACG)
Annual Scientific Meeting , Washington, DC
16.25 AMA PRA Category 1 Credits™

2011 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Washington, DC
13.25 AMA PRA Category 1 Credits™

2010 American College of Gastroenterology (ACG)
Annual Scientific Meeting , San Antonio, TX.
16.25 AMA PRA Category 1 Credits™

2010 American College of Gastroenterology (ACG)
Physician Postgraduate Course, San Antonio, TX .
13.25 AMA PRA Category 1 Credits™

2009 American College of Gastroenterology (ACG)
Annual Scientific Meeting San Diego, CA.
16.25 AMA PRA Category 1 Credits™

2009 American College of Gastroenterology (ACG)
Physician Postgraduate Course, San Diego, CA.
13.25 AMA PRA Category 1 Credits™

2008 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Orlando, FL.
16.25 AMA PRA Category 1 Credits™

2008 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Orlando, FL

13.25 AMA PRA Category 1 Credits™

2007 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Philadelphia, PA.
16.25 AMA PRA Category 1 Credits™

2007 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Philadelphia, PA.
13.25 AMA PRA Category 1 Credits™

CURRICULUM VITAE

Edmond T. Conway, FNP-C

CONTINUING MEDICAL EDUCATION COURSES (CME)

2006 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Las Vegas, NV.
16.25 AMA PRA Category 1 Credits™

2006 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Las Vegas, NV.
13.25 AMA PRA Category 1 Credits™

2005 American Association for the Study of Liver Diseases (AASLD)
The Liver Meeting, San Francisco, CA.

2004 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Scottsdale, AZ.
16.25 AMA PRA Category 1 Credits™

2004 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Scottsdale, AZ..
13.25 AMA PRA Category 1 Credits™

2003 American College of Gastroenterology (ACG)
Annual Scientific , Baltimore, MD
16.25 AMA PRA Category 1 Credits™

2003 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Baltimore, MD
13.25 AMA PRA Category 1 Credits™

2002 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Scottsdale, AZ..
16.25 AMA PRA Category 1 Credits™

2002 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Scottsdale, AZ..
13.25 AMA PRA Category 1 Credits™

2001 American College of Gastroenterology (ACG)
Annual Scientific Meeting, Las Vegas, NV.
16.25 AMA PRA Category 1 Credits™

CURRICULUM VITAE

Edmond T. Conway, FNP-C

CONTINUING MEDICAL EDUCATION COURSES (CME)

2001 American College of Gastroenterology (ACG)
Physician Postgraduate Course, Las Vegas, NV.
13.25 AMA PRA Category 1 Credits™

INVESTIGATIONAL/STUDY PROTOCOLS:

1. "A phase III, multi-national, multi-site, double-blind, placebo controlled, 28 week study to assess the safety and efficacy of the engineered human anti-TNF_{cx} antibody, CDP571 (10 mg/kg), in patients with active Crohn's disease. Protocol Number CDP571-015.

2. "Prevention of sporadic colorectal adenomas with Celecoxib." Protocol Numbers NCI #N01-CN-95015, Searle #IQ4-99-02-005, WIRB 991136.

3. "Pegylated interferon and ribavirin for HCV treatment failure." Schering. Protocol Number 202-02-00.

4. "Comparison of PEG interferon alfa-2b plus ribavirin given as a fixed dose or on a weight optimized basis for treatment of chronic hepatitis C in previously untreated adult subjects BB-IND#-9243." Schering. Protocol Number 244-11-00.

5. "Use of Peg-Interferon alfa-2b and Ribavirin for Treatment of Patients with Chronic Hepatitis C with Normal ALT Levels. Schering.

6. A Comparison of the Safety and Efficacy of Two Doses of Peg-Interferon alfa-2b (Peg-Intron: 1.5 mcg/kg vs. 3.0 mcg/kg) in Combination with Ribavirin (Rebetol) for Treatment of Chronic Hepatitis C Patients. Schering.

7. Phase II Study of Long Term Peg-Intron For Patients Who Have Failed To Respond to Rebetron/Interferon with Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C. Schering.

8. Does Induction Peg-Intron In Combination with Rebetol Enhance The Sustained Response Rates in Patients With Chronic Hepatitis C. Schering.

9. Adalimumab Injection TNF Antibody SQ. Indication: Crohn's disease. Protocol Number M02-404. Abbott.

10. Humanised anti-TNF PEG conjugate CDP870 400 mg sc. Indication: Crohn's disease. Protocol Number CDP870-131. Celltech.

11. Humanised anti-TNF PEG conjugate CDP870 400 mg sc. Indication: Crohn's disease. Protocol Number CDP870-133. Celltech.

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

12. Humanised anti-TNF PEG conjugate CDP870 400 mg sc. Indication: Crohn's disease. Protocol Number CDP870-134. Celltech.

13. Progesterone Analogue PO. Indication: Crohn's disease. Protocol Number CBP-1011-00-02. InKine.

14. TC-2403-12 Enema Nicotine. Indication: UC/Distal. Protocol Number TC-2403-12-CRD-001. Targacept.

15. Mesalamine Rectal Gel. Indication: UC. Protocol Number ASGELUC02-02. Axcan.

16. OPC-6535- PO TNF Suppressor. Indication: UC/Any. Protocol Number 197-02-218. Otsuka.

17. Lansoprazole 30 mg QD + Naproxen 500 mg vs. Celecoxib 200 mg QD. Indication: Osteoarthritis. Protocol Number LAN-0003-0041. TAP.

18. "Multicenter, Randomized, Open-Label, Controlled Study of the Effect of Treatment with Once Weekly Pegasys® Plus Daily Copegus® with or without Concomitant Pioglitazone (Actos®) on Early Viral Kinetics in treatment-Naïve Patients with Chronic Hepatitis C (Genotype-1 HCV Infection) and Insulin Resistance" Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number ML21301D.

19. "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naive Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B Virus." Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number CI-PSI-5268-06-305.

20. "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naive Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B Virus." Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number CI-PSI-5268-06-306.

21. Protocol HGS1008-C1060. "A Phase 3, Randomized, Multi-Center Study to Evaluate theEfficacy and Safety of Albumin Interferon, Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-INF@2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1". Principal Investigator: Robert W. Herring, Jr., M.D.

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

22. "A Randomized, Double-blind, Placebo-controlled Study of AGI-003 (Averapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number AGI003-003.

23. "A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg versus Esomeprazole 40 mg of Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease". Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number E3810-G000-301/302/303.

24. "A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)". Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number E3810-G000-305.

25. "A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety and Tolerability of Rabeprazole ER 50 mg with Placebo in Subjects with Symptomatic Gastroesophageal Reflux Disease (sGERD) Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number E3810-G000-307.

26. "A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virological Response in Patients with Chronic Hepatitis C, Genotype 2 or 3 who do not Achieve a Rapid Viral Response". Principal Investigator: Robert W. Herring, Jr., MD. Sub-Investigator: Edmond T. Conway, FNP-C. Protocol Number MV21542.

27. NV20536 - A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection

28. PP25213 - INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) with or without Copegus in Interferon Naïve HCV Genotype 1 Infected Patients.

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

29. A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and Copegus® versus Pegasys® and Copegus® alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1or 4 Virus Infection

30. Anadys, Protocol ANA598-505 "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered with Pegylated Interferon and Ribavirin in Genotype 1 Patients with Chronic Hepatitis C Infection"

31. GS-US-248-0120: A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection

32. GS-US-256-0124: A Phase 2b Randomized, Double Blind Palcebo Controlled Evaluating Response Guided Therapy using Combinations of Oral Antivirals Study of (GS-5885,GS-9451,Tegobuvir and/or Gs9451) with Peinterferon and Ribavirin (RBV) in Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection

33. GS-US-256-0148: A Phase 2b Randomized, Double Blind, Placebo Controlled Trial Evaluating Response Guided Therapy of GS-5885 Alone or in Combination with GS-9451, and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection

34. WV21913 A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (DNV/r) and Copegus®, in Combination with the HCV Polymerase Inhibitor Prodrug RO5024048 and/or Pegasys® in Chronic Hepatitis C Genotype 1 Patients Who Failed with a Previous Course of Peginterferon alfa plus Ribavirin Combination Therapy

35. Gilead, P2938-0721 (Quantum): "An International, Multi-Center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients with Chronic HCV Infection."

36. Merck, P05063 Site 188 Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C".

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

37. Gilead, Protocol P7977-1231 (Fission): "A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection".

38. Roche Protocol NV19865C. "A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naïve Patients with Chronic Hepatitis C Genotype I Virus Infection". Principal Investigator: Robert W. Herring, Jr., M.D.

39. A Phase II, Multicenter, Randomized, Open-Label, Active-Control, Dose-Ranging Study of Interferon-Alfa-2b Given Via Continuous Subcutaneous Infusion in Subjects with Hepatitis C Virus Genotype 1 Infection Principal Investigator: Robert W. Herring, Jr., M.D.

40. Schering-Plough/Merck, Protocol P06086 "Boceprevir and Peg interferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naïve Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia". Principal Investigator: Robert W. Herring, Jr., M.D.

41. Roche, NV22688B-row Long Term Monitoring Study to Evaluate the Persistence of Direct Acting Antiviral (DAA) Treatment Resistant Mutations or the Durability of Sustained Viral Response (SVR) in patients treated with DAA-containing regimens for Chronic Hepatitis C Infection (CHC) Principal Investigator: Robert W. Herring, Jr., M.D.

42. MCH-02-001 A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH Principal Investigator: Robert W. Herring, Jr., M.D.

43. Idera Pharmaceuticals, Inc. Protocol 2125-001:A Phase 1, Multi-center, Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients Unresponsive to Standard Treatment with Pegylated Interferon and Ribavirin Principal Investigator: Robert W. Herring, Jr., M.D.

44. Roche, NV21928B: "An Open-label, Multicenter, protocol providing with Pegasys® as monotherapy or in combination with Copegus® for patients Chronic Hepatitis C who have participated in previous Roche of Roche partner protocols". Principal Investigator: Robert W. Herring, Jr., M.D.

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

45. "Efficacy and Safety of Mericitabine (MCB) in Combination with PegIFNα-2A/RBV in G1/4 Treatment Naïve RCV Patients: Final Analysis From the PROPEL Study." Wedemeyer, H., Jensen, D., Herring, Jr., R., Ferenci, P., Mang-Ming, M., Zeuzem, S., Rodriguez-Torres, M., Bzowej, N., Pockros, P., Vierling, J., Ipe, D., Thommes, J.

46. Gilead, GS-US-248-0122: "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection".

47. Gilead, GS-US-248-0123: "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve a Sustained Virological Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection".

48. Gilead, GS-US-334-0110**: "**A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 with Peginterferon Alfa 2a and Ribavirin for 12 Weeks in treatment-Naïve Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection"

49. Gilead, GS-US-334-0108: A Phase 3, Multicenter, Randomized, Double-Blind Study To Investigate The Efficacy And Safety Of GS-7977 + Ribavirin For 12 Or 16 Weeks In Treatment Experienced Subjects With Chronic Genotype 2 Or 3 HCV Infection

50. Vertex, VX11-222-108 : "A Multicenter, Randomized, Open-label, Phase 2b Study to Evaluate the Efficacy and Safety of Two Regimens of All-oral Triple Therapy (VX-222 in Combination With Telaprevir [Incivek™]and Ribavirin[Copegus®])in Treatment-Naïve Subjects With Genotype 1a Chronic Hepatitis C".

51. Achillion, ACH102-005: "A phase 1b, open-label, pilot study to evaluate the safety, tolerability and antiviral activity of oral ACH-0143102 administered in combination with ribavirin after 12 weeks of dosing in treatment naïve subjects with chronic hepatitis C virus infection genotype 1b".

52. Achillion, ACH102-007: "A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naïve Subjects with Chronic Hepatitis C Genotype-1 Viral Infection"

53. Gilead, GS-US-334-0109 "An Open-Label Study of GS-7977 + Ribavirin with or without Peginterferon Alfa-2a in Subjects with Chronic HCV Infection who participated in prior Gilead HCV Studies"

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

54. Gilead, GS-US-334-0107: "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon"

55. Gilead, GS-US-337-0102 (ION 1): "A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection"

56. Gilead, GS-US-337-0109 (ION 2) "A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination □□Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection"

57. Gilead, GS-US-337-0108 (ION 3) "A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection

58. Gilead, GS-US-342-0102: "A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection"

59. Gilead, Protocol GS-US-342-0109: "A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects with Chronic HCV Infection"

60. Abbott, M14-002 (Abbvie): "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)"

61. Gilead, GS-US-334-0153: "A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection". IND No: 106,739

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

62. Merck, MK-5172, Protocol 003-02: " A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naive Patients with Chronic Genotype 1 Hepatitis C Virus Infection"

63. Bristol-Meyers Squibb, Protocol AI443-102, "A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C"

64. Bristol-Meyers Squibb, Protocol AI443-113, "A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis"

65. Gilead, GS-US-337-1118: "An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin For 12 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study".

66. Ferring International Pharmascience Center US, Inc.,; Protocol 000080: "A double-blind, Randomised , Placebo-controlled,Pase 3Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibate 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period".

67. Kadmon Corporation; Protocol Number RBV-201: "A Phase 2, Multicenter, Open-Label, Randomized, Parallel-Group Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of Oral Ribavirin (RBV) Administered Once Daily Versus Oral Ribasphere® Administered Twice Daily in Combination with Sofosbuvir 400 mg in Subjects With Genotype 2, Chronic Hepatitis C".

68. Hologic Incorporated; Protocol #: P10433-HCVQPS-CSP-01: "Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay".

69. Boehringer Ingelheim; Protocol #: 1311.6: "A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066, an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naïve to, or Were Previously Treated With Anti-TNF Therapy".

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

70. Pfizer; Protocol #: A3191172 (PRECISION): "A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen".

71. Evoke Pharma; Protocol #: METO-IN-003: "A multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women with Symptoms Associated with Diabetic Gastroparesis".

72. Evoke Pharma; Protocol #: METO-IN-004: "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men with Symptoms Associated with Diabetic Gastroparesis".

73. Janssen Research & Development, LLC; Protocol #: CNTO136ARA3005; Phase 3; "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects With Active Rheumatoid Arthritis"

74. Salix Pharmaceuticals; Protocol #: RNLC2131; "A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis"

75. Janssen Research and Development LLC.; Protocol #: TMC435HPC3017; "A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve and -Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis".

76. Janssen Research and Development LLC; Protocol #: TMC435HPC3018; "A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve or -Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis".

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

77. Merck; Protocol #: MK5172-068; "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin (P/R) with Chronic HCV GT1, GT4, GT5, and GT6 Infection"

78. Synergy Pharmaceuticals Inc.; Protocol #: SP304203-03; "A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation" (The National CIC3 Study)

79. AbbVie Inc.; Protocol #: M14-867; "An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection"

80. AbbVie Inc.; Protocol #: M14-868; "An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection"

81. Gilead; Protocol # GS-US-342-1138 (ASTRAL 1); A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV"

82. Gilead; Protocol # GS-US-342-1139 (ASTRAL 2); "A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infection"

83. Targacept Inc.; Protocol # TC-6499-12-CLP-005; "A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Assess The Effects of TC-6499 On Gastric Emptying Time In Diabetic Subjects With Gastroparesis (Pro00009709)"

84. Gilead: Protocol # GS-US-342-1137 (ASTRAL 4) "A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis"

85. Gilead: Protocol # GS-US-367-1168 "A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection"

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

86. Gilead: Protocol # GS-US-367-1169 "A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection"

87. Gilead: Protocol # GS-US-342-1446 "An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection"

88. Gilead: Protocol # GS-US-342-1553 "An Open-Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination with Ribavirin For 24 weeks In Chronic HCV Infected Subjects Who Participated In Prior Gilead-Sponsored HCV Treatment Studies" Primary Investigator

89. Tobira Therapeutics: Protocol # 652-2-203 (CENTAUR) "Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis"

90. Intercept Pharmaceuticals, Inc.: Protocol # 747-302" A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis"

91. Theravance Biopharma R & D, Inc.: Protocol # 0099 "A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopatihic Gastroparesis"

92. Genentech: Protocol # GA28949 "Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab compared with Adalimumab and Placebo in Patients with Moderate to Severe Ulcerative Colitis who are Naïve to TNF Inhibitors"

93. Genentech: Protocol # GA28951 "An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis patients previously Enrolled in Etrolizumab Phase III Studies"

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

94. Salix Pharmaceuticals, Inc: Protocol # RECD3125 "A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, Study to Assess the Efficacy and Safety of Rifaximin Delayed Release Tablets for the Induction and Maintenance of Remission in Subjects With Active Moderate Crohn's Disease"

95. Synergy Pharmaceuticals Inc.: Protocol # SP-333101-04 "A Phase 1b, Exploratory, Double-Blind, Placebo-Controlled, Four-Week Study of Rectally Administered SP-333 for the Treatment of Patients with Mildly to Moderately Active Left-Sided Ulcerative Colitis"

96. Braintree Laboratories Inc.: Protocol # BLI400-301 "A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults"

97. Hologic Incorporated; Protocol #: P10434-HBVQPS-CSP-01: "Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay"

98. Celgene Corporation: Protocol # GED-0301-CD-001 "A Randomized, double-blind, multicenter study to explore the effect of GED-0301 on endoscopic and clinical outcomes in subjects with active Crone's Disease".

99. Merck: Protocol # MK5172-017 "A Long-Term Follow-up Study to Evaluate the Durability of Virology Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial".

100. Bristol-Myers Squibb Research and Development: Protocol # MB130045 "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults with Non-alcoholic Steatohepatitis".

101. AbbVie Inc.: Protocol #: M13-576. "A Follow-up Study to Assess Resistance and durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection ".

102. Gilead: Protocol # GS-US-367-1171 (POLARIS 1): "A Phase 3, Global, Multicenter, Randomized, Open-LabelStudy to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis".

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

103. Gilead: Protocol # GS-US-367-1172 (POLARIS 2): " A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV Infection". .

104. Gilead: Protocol # GS-US-367-1173 (POLARIS 3): "A Phase 3, Global, Multicenter, Randomized, Open-Labe Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis". .

105. Gilead: Protocol # GS-US-367-1170 (POLARIS 4) "A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor" .

106. AbbVie Inc.: Protocol # M13-590 "A Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection (ENDURANCE-1)".

107. Arrowhead:..Protocol # Heparc 2004 "A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection".

108. Celgene Corporation: Protocol # GED-0301-UC-002 "A Phase 2, Open-Label, Multicenter study to explore the efficacy and safety of Mongersen (GED-0301) in subjects with active Ulcerative Colitis".

109. Ardelyx, Inc.: Protocol # TEN-01-301 "A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study with a 4-Week randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)".

110. Janssen Research & Development: Protocol # CNTO1275UCO3001; (Phase 3) "A Phase 3, Randomized,Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis"

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

111. Synergy Pharmaceuticals Inc.: Protocol # SP-304203-04 "Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS_C)"

112. Synergy Pharmaceuticals Inc.: Protocol # SP-304203-01 "An Open-Label, Long-Term Safety and Tolerability Study of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)"

113. Ferring International: Protocol # 000174 "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis"

114. Ferring International: Protocol # 000175 "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Ulcerative Colitis"

115. Ardelyx, Inc.: Protocol # TEN-01-302 "A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)".

116. Ardelyx, Inc.: Protocol # TEN-01-303 "An Open Long-Term Safety Study of Tenapanor for Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)".

117. Pfizer: Protocol # A4091056 "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee"

118. Pfizer: Protocol # A4091064 "A Phase 3, Multicenter, Long-Term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement"

119. Synergy Pharmaceuticals Inc.: Protocol # SP304203-06 "A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)"

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

120. Intercept Pharmaceuticals, Inc.: Protocol # 747-303 **"**A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis" Sub Investigator

121. AbbVie Inc.: Protocol # M13-594 "Study Title/Description: A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection" Sub Investigator

122. Novartis Research and Development: Protocol # CLMB763X2201 "A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (NASH)" Sub Investigator

123. Shire Human Genetic Therapies, Inc.: Protocol # SHP626-201 "A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)" Sub Investigator

124. NuSirt Sciences, Inc.: Protocol # NS-0200-01 "A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Effect Of Two Fixed-dose Leucine, Metformin and Sildenafil Combinations (NS-0200) Versus Placebo On Hepatic Fat Content Assessed By Proton-Density-Fat-Fraction In Patients With Non-Alcoholic Fatty Liver Disease" Sub Investigator

125. Pfizer: Protocol # A4091059 "A Phase 3 Randomized, Double Blind, Placebo and Active-Controlled, Multicenter, Parallel-Group Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects with Chronic Low Back Pain" Sub Investigator

126. Braintree Laboratories Inc.: Protocol # BLI400-303 "An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults" Sub Investigator

127. CelgeneCorporation: Protocol # CC-1004-UC-001 "A Phase 2, Randomized, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects with Active Ulcerative Colitis" Sub Investigator

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

128. MedImmune: Protocol # D5170C00002 "A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy" Sub Investigator

129. Gilead: Protocol # GS-US-418-3898 Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis" Sub Investigator

130. Gilead: Protocol # GS-US-418-3899 "A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis" Sub Investigator

131. Gilead: Protocol # GS-US-419-3895 "Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease" Sub Investigator

132. Gilead: Protocol # GS-US-419-3896 "A Long-Term Extension Study to Evaluate the Safety of Filgotinib" Sub Investigator

133. Gilead: Protocol# GS-US-384-3914, "A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) (Pro00017529)" Sub Investigator

134. Gilead: Protocol # GS-US-384-1943, "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (Pro00020074)" Sub Investigator

135. Gilead: Protocol # GS-US-384-1944, "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)" Sub Investigator

136. Gilead: Protocol # GS-US-402-1852, "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH)" Sub Investigator

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

137. Gilead: Protocol # GS-US-426-3989, "A Phase 2, Randomized, Double-Blind Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects with Nonalcoholic Steatohepatitis" Sub Investigator

138. Gilead: Protocol # GS-US-320-4018, "A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed" Sub Investigator

139. Vanda Pharmaceuticals Inc.: Protocol # VP-VLY-686-2301, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Tradipitant In Relieving Symptoms of Gastroparesis"

140. RedHill Biopharma Ltd.: Protocol # RHB-105-02, "A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter pylori (H. pylori) Infection"

141. Genfit: Protocol # GFT505-315-1, "A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis"

142. Intercept: Protocol # 747-304, "A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis"

143. Allergan Sales, LLC: Protocol # RLM-MD-01, "A 12-week, Randomized, Double-blind, Placebo controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis"

144. Allergan Sales, LLC: Protocol # RLM-MD-03, "A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis"

145. Allergan Sales, LLC: Protocol # RLM-MD-04, "A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis"

146. Gilead: Protocol # GS-US-454-4378, "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)"

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

147. Celgene: Protocol # RPC01-3201, "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod As Induction Therapy for Moderately To Severely Active Crohn's Disease Study"

148. Celgene: Protocol # RPC01-3203, "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod As Maintenance Therapy for Moderately To Severely Active Crohn's Disease Study"

149. Celgene: Protocol # RPC01-3204, "A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease Study"

150. Regeneron Pharmaceuticals: Protocol # R475-PN-1612, "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee"

151. AbbVie Inc.: Protocol # M14-430, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease Who Completed the Studies M14-431 or M14-433"

152. AbbVie Inc.: Protocol # M14-431, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy Incorporating Amendments 1, 2, and 3"

153. AbbVie Inc.: Protocol # M14-433, "Clinical Study Protocol M14-433A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy Incorporating Amendments 1, 2, and 3"

154. AbbVie Inc.: Protocol # M14-533 A Phase 3 multicenter, Long-Term Extension study to evaluate the long-term safety and efficacy of Upadacitinib (ABT-494) in subjects with ulcerative Colitis"

155. AbbVie Inc.: Protocol # M14-234 A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Upadacitinib (ABT-494) for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis

INVESTIGATIONAL/STUDY PROTOCOLS: (Continued)

156. AbbVie Inc.: Protocol # M14-675, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis"

157. Laboratory for Advanced Medicine, Inc. (LAM): Protocol # 001-2018, "Collection of Blood from Healthy Patients, Patients with Benign Desease and Patients with Cancer"

158. Vanda Pharmaceuticals, Inc.: Protocol # VP-VLY-686-3101, "A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study Of The Neurokinin-1 Receptor Antagonist VLY-686 In Patients With Atopic Dermatitis"

159. Seres Therapeutics: Protocol # SERES-201, "A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis"